MSD has announced that
the European Commission has
approved Ketruda (pembrolizumab)
for the treatment of advanced
(unresectable or metastatic)
melanoma in adults.
The decision allows marketing
of pembrolizumab in all 28 EU
member states at the approved
dose of 2 mg/kg every three weeks.
Keytruda is available on the PBS in
Australia from 01 Sep (PD 29 Jun).The above article was sent to subscribers in Pharmacy Daily's issue from 24 Jul 15 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 24 Jul 15
MEDICATION management platform MedAdvisor Limited (MDR) showed strong financial performance for the quarter concluded on 31 Mar 2024, with operating revenue up 42% to $24.2 million from $17 million for the same period last year.
PHARMACIES in regional areas need a restructure of the 8CPA Community Service Obligation (CSO) to help fund them to support their workforce and deliver services, says the Remote and Isolated Pharmacist Association Australia (RIPAA).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.